• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Home >> Signaling Pathways >> Proteases >> HSP >> IPI-504 (Retaspimycin hydrochloride)
Related Products
IPI-504 (Retaspimycin hydrochloride)
Hsp90 inhibitor,novel, potent,selective

IPI-504 (Retaspimycin hydrochloride)

Catalog No. A4061
Size Price Stock Qty
10mM (in 1mL DMSO) $350.00 In stock
5mg $175.00 In stock
10mg $315.00 In stock
50mg $795.00 In stock
100mg $1,395.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Product Citations

1. Debruyne, D. N., et al. "ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT." Oncogene (2015). PMID:26616860

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

IPI-504 (Retaspimycin hydrochloride)

Related Biological Data

IPI-504 (Retaspimycin hydrochloride)

Biological Activity

Description Retaspimycin Hcl(IPI504 Hcl) is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities.
Targets HSP90          


Cell experiment [1]:

Cell lines

Glioma cell lines (D-54 MG and U-251 MG cells)

Preparation method

This compound was soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reaction Conditions

1 or 2.5 μM; 24 or 48 hrs


In glioma cells, IPI-504 inhibited cell proliferation through increasing sub-G1 population of cells and dose-dependently inducing fragmented DNA of the apoptotic cells.

Animal experiment [1]:

Animal models

Mice bearing human brain tumor D-54MG xenografts

Dosage form

100 mg/kg; i.p.; b.i.d., twice weekly or 5/2/5 schedule (5 days on, 2 days off, and then 5 days on), for 6 weeks


In immunocompromised mice, IPI-504 mildly attenuated tumor growth.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. J Neurooncol. 2014 Dec;120(3):473-81.

IPI-504 (Retaspimycin hydrochloride) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


IPI-504 (Retaspimycin hydrochloride) Molarity Calculator



Chemical Properties

Cas No. 857402-63-2 SDF Download SDF
Synonyms IPI 504, IPI504
Chemical Name [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6,20,22-trihydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16-oxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(22),8,12,14,18,20-hexaen-10-yl] carbamate;hydrochloride
Formula C31H46ClN3O8 M.Wt 624.2
Solubility >26.1mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request


Retaspimycin hydrochloride (also known as IPI-504), a hydroquinone hydrochloride salt derivative of 17-AAG, is a novel, potent and selective inhibitor of heat shock protein 90(Hsp90) that binds to the amino-terminal ATP/ADP-binding site of Hsp90. As a highly water-soluble version of 17-AAG, IPI-504 (solubility > 200 mg/mL) does not need prior dissolution in organic solvents and hence can be delivered in high concentrations. Once in the systemic circulation, IPI-504 is deprotonated and converted into the free base IPI-504 which is subsequently oxidized to 17-AAG. IPI-504 potently inhibits proliferation in several tumor cell lines with 50% inhibition concentration IC50 values ranging from 10-40 nmol/L and has been used for the treatment of gastrointestinal stromal tumors, soft-tissue sarcomas and non-small cell lung cancer.


Britt Erika Hanson and David H Vesole. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investi. Drugs (2009) 18(9): 1375-1383

David Siegel, Sundar Jagannath, David H. Vesole, Ivan Borello, Amitabha Mazumder, Constantine Mitsiades, Jill Goddard, Joi Dunbar, Emmanuel Normant, Julian Adams, David Grayzel, Kenneth C. Anderson and Paul Richardson. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia & Lymphoma, 2011; 52(12): 2308-2315

Ching Ching Leow, Jon Chesebrough, Karen T. Coffman, Christine A. Fazenbaker, John Gooya, David Weng, Steve Coats, Dowdy Jackson, Bahija Jallal and Yong Chang. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 2009; 8: 2131-2141